DYNT $1.28...Earnings next week...and will be good. The company has released an umprecedented 10 new high-margin products in recent months. These new products will increase revenues by at least 10% according to management. With a reduction of R&D from record levels DYNT will likely earn 15c/share in 2007.
DYNT is one of the safest stock you will find under $2. The company believes the stock is too undervalued and they have a stock buyback that they activate when the stock reaches under $1.3. They do that to prevent manipulation and to get too close to $1. They bought over 50,000 shares this year and have money approved for about 250,000 more shares
Now this company is ready to turn the corner. They predicted at least 10% revenue increase for 2007 compared to 2006. 2006 was a year of transition and they invested a record $1.7M in R&D. This led to the recent release of many new products....the highest number of new products in company history. These products will start showing their positive effect on revenues and net income starting with 1Q 2007 to be reported in early November.
In addition to a healthy revenue growth, DYNT is likely to produce a net income of about 15c/share in 2007. This is because the margins for the new products will be higher and the company will reduce R&D expenses by about 5c/share.
DYNT has a strong balance sheet, a low float, and it is currently trading at a very low 0.5 P/s for a profitable company with strong growth prospects.
DYNT HIGHLIGHTS:
* DYNT IS THE LEADER IN LIGHT THERAPY FOR PAIN MANAGEMENT
* FDA APPROVED and PATENTED PRODUCTS
* NEW PRODUCTS WILL YIELD SUBSTANTIAL GAINS IN REVENUE AND NET INCOME STARTING with 1Q 2007
* PROFITABLE AND TRADING AT 0.5 P/S
* STRONG BALANCE SHEET
* STOCK BUYBACK IS ONGOING.
SELECTED COMPANY COMMENTS FROM 2006 EARNINGS RELEASE and CC
..."New products introduced during the past year include the Dynatron 702, a stand-alone light therapy device, as well as the new DX9 combination traction and light therapy system. The DX9 system combines the benefits of infrared light therapy using the Dynatron 702 with decompression therapy using the Company's TX900 Traction device. This unique combination of modalities has been reported to be highly effective in the treatment of back pain..."
"Dynatronics also introduced the Dynatron Xp light pad in 2006. This popular product is capable of treating a much larger area than can be treated by other devices. It is 14 times more powerful than light probes currently on the market and makes unattended patient therapy possible..."
"Looking ahead to fiscal 2007, we are pleased to have begun the year with the July 2006 introduction of the new Dynatron X3 infrared light therapy device," said Larry K. Beardall, executive vice president for sales and marketing. "In addition, we plan to introduce the much anticipated DX2 proprietary traction device soon. The DX2 incorporates patent-pending technology and will utilize the new T4 treatment table which is specially designed for traction and decompression therapies. The T4 treatment table is scheduled for introduction in November 2006."
The new DX2 is currently undergoing clinical beta testing and has been previewed at several national trade shows. "Interest in the DX2 from practitioners at the national trade shows has been substantial," reported Beardall. "While the development effort has taken longer than anticipated, we believe this innovative approach to treating back pain will prove to be a great benefit to patients."
ABOUT DYNT:
DYNT is the leader in the area of light therapy for pain management. DYNT's Light therapy products are FDA-approved. Because light therapy is non-invasive and does not have adverse effects, it is an ideal replacement for dangerous drugs like Vioxx, and Celebrex to address Rheumatism and similar types of pain. Light therapy is also used for carpal syndrome and a number of muscle/nerve/bone types of pain.
Light Therapy has been used extensively throughout the world for more than twenty years. Also known as cold laser or phototherapy, Light Therapy is backed by extensive research with over 500 published studies covering a number of soft-tissue injuries, pain, and inflammatory conditions.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.